Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 APPROXIMATELY 500,000 U.S. PATIENTS ARE DIAGNOSED WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB), A PROGRESSIVE DISEASE THAT CAN LEAD TO PERMANENT LUNG DAMAGE   BRINSUPRI 10 MG AND 25 MG DOSES APPROVED FOR THE TREATMENT OF NCFB   BRINSUPRI, A FIRST-IN-CLASS DPP1 INHIBITOR TARGETING NEUTROPHILIC INFLAMMATION, IS AVAILABLE BY PRESCRIPTION THROUGH A COMPREHENSIVE SPECIALTY PHARMACY NETWORK   INSMED TO HOST INVESTOR CONFERENCE CALL TODAY AT 12:00 PM ET  BRIDGEWATER, N.J. , AUG. 12, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVERFIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED FIRST-IN-CLASS BRINSUPRI(BRENSOCATIB 10 MG AND 25 MG TABLETS), AN ORAL, ONCE-DAILY TREATMENT FOR NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB) IN ADULTS AND CHILDREN 12 YEARS AND OLDER.

FDA APPROVES BRINSUPRI (BRENSOCATIB) AS THE FIRST AND ONLY TREATMENT FOR NON-CYSTIC FIBROSIS BRONCHIECTASIS, A SERIOUS, CHRONIC LUNG DISEASE

ARIKAYCE (AMIKACIN LIPOSOME INHALATION SUSPENSION) TOTAL REVENUE OF $107.4 MILLION FOR THE SECOND QUARTER OF 2025, REFLECTING 19% GROWTH OVER THE SECOND QUARTER OF 2024 NDA FOR BRENSOCATIB IN PATIENTS WITH BRONCHIECTASIS REMAINS ON TRACK, WITH A PDUFA TARGET ACTION DATE OF AUGUST 12, 2025 TPIP PROGRAM ADVANCING WITH PHASE 3 STUDIES PLANNED TO BEGIN FOR PH-ILD IN THE SECOND HALF OF 2025 AND FOR PAH IN EARLY 2026 TOPLINE DATA ANTICIPATED FOR PHASE 2B BIRCH STUDY OF BRENSOCATIB IN PATIENTS WITH CRSSNP BY THE END OF 2025 COMPANY REITERATES 2025 GLOBAL ARIKAYCE REVENUE GUIDANCE RANGE OF $405 MILLION TO $425 MILLION, REFLECTING DOUBLE-DIGIT GROWTH COMPARED TO 2024 BRIDGEWATER, N.J. , AUG. 7, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND PROVIDED A BUSINESS UPDATE.

INSMED REPORTS SECOND-QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIDGEWATER, N.J. , JULY 24, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL RELEASE ITS SECOND-QUARTER 2025 FINANCIAL RESULTS ONTHURSDAY, AUGUST 7, 2025.

INSMED TO HOST SECOND-QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, AUGUST 7, 2025

BRIDGEWATER, N.J. , JUNE 11, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT PRICED AN UNDERWRITTEN PUBLIC OFFERING OF 7,812,500 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $96.00 PER SHARE.

INSMED ANNOUNCES PRICING OF $750 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIDGEWATER, N.J. , JUNE 11, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT INTENDS TO OFFER AND SELL $650 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.

INSMED ANNOUNCES PROPOSED $650 MILLION PUBLIC OFFERING OF COMMON STOCK

THE STUDY MET PRIMARY AND ALL SECONDARY EFFICACY ENDPOINTS STATISTICALLY SIGNIFICANT 35% PLACEBO-ADJUSTED REDUCTION FROM BASELINE IN PULMONARY VASCULAR RESISTANCE FOR THE PRIMARY ENDPOINT (P

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2B STUDY OF TREPROSTINIL PALMITIL INHALATION POWDER (TPIP) AS ONCE-DAILY THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

BRIDGEWATER, N.J. , JUNE 4, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO 150 NEW EMPLOYEES.

INSMED REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BRIDGEWATER, N.J. , MAY 28, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE 2025 GOLDMAN SACHS ANNUAL GLOBAL HEALTHCARE CONFERENCE IN MIAMI ON WEDNESDAY, JUNE 11, 2025, AT 9:20 A.M.

INSMED TO PRESENT AT THE 2025 GOLDMAN SACHS ANNUAL GLOBAL HEALTHCARE CONFERENCE

  INSMED PRESENTED 11 ABSTRACTS AT ATS 2025 FROM ACROSS ITS RESPIRATORY PORTFOLIO, INCLUDING DATA ON ARIKAYCE , TPIP AND HEALTH ECONOMICS AND OUTCOMES RESEARCH   BRIDGEWATER, N.J. , MAY 21, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, PRESENTED 11 NEW ABSTRACTS AT THE AMERICAN THORACIC SOCIETY (ATS) 2025 INTERNATIONAL CONFERENCE, WHICH TOOK PLACE MAY 18-21 IN SAN FRANCISCO, INCLUDING THREE PRESPECIFIED SUBGROUP ANALYSES FROM THE PHASE 3 ASPEN TRIAL OF BRENSOCATIB IN NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFBE), SIGNALING THE CONSISTENCY OF EFFICACY AND SAFETY OUTCOMES ACROSS DIVERSE CLINICAL PROFILES.

BRENSOCATIB SHOWS CONSISTENT EFFICACY AND SAFETY ACROSS THREE PRESPECIFIED SUBGROUPS IN NEW DATA FROM LANDMARK ASPEN STUDY

ARIKAYCE (AMIKACIN LIPOSOME INHALATION SUSPENSION) TOTAL REVENUE OF $92.8 MILLION FOR THE FIRST QUARTER OF 2025, REFLECTING 23% GROWTH OVER THE FIRST QUARTER OF 2024 NDA FOR BRENSOCATIB IN PATIENTS WITH BRONCHIECTASIS REMAINS ON TRACK, WITH A PDUFA TARGET ACTION DATE OF AUGUST 12, 2025 PHASE 2B STUDY OF TPIP IN PATIENTS WITH PAH COMPLETED; TOPLINE DATA EXPECTED IN JUNE 2025 ENROLLMENT COMPLETED FOR PHASE 2B BIRCH STUDY OF BRENSOCATIB IN PATIENTS WITH CRSSNP; TOPLINE DATA ANTICIPATED BY THE END OF 2025 MAA FILINGS FOR BRENSOCATIB IN PATIENTS WITH BRONCHIECTASIS ACCEPTED BY EMA AND MHRA COMPANY REITERATES 2025 GLOBAL ARIKAYCE REVENUE GUIDANCE RANGE OF $405 MILLION TO $425 MILLION, REFLECTING DOUBLE-DIGIT GROWTH COMPARED TO 2024 BRIDGEWATER, N.J. , MAY 8, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND PROVIDED A BUSINESS UPDATE.

INSMED REPORTS FIRST-QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIDGEWATER, N.J. , APRIL 29, 2025 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE BOFA SECURITIES 2025 HEALTH CARE CONFERENCE IN LAS VEGAS ON TUESDAY, MAY 13, 2025, AT 2:20 P.M.

Insmed Incorporated

INSM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Insmed Incorporated

INSM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

INSM